Pablo Pánico

Dr. Pablo Pánico

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
PPPablo Pánico
Pablo Pánico
POPatricia Ostrosky-Wegman
Patricia Ostrosky-Wegman
ASAna María Salazar
Ana María Salazar

Verified
Journal Article
Open access
PDF file
JSJazmin Samario
Jazmin Samario
Carlos LarquéCarlos Larqué
Carlos Larqué
PPPablo Pánico
Pablo Pánico
Rosa Isela Ortiz-HuidobroRosa Isela Ortiz-Huidobro
Rosa Isela Ortiz-Huidobro
Myrian VelascoMyrian Velasco
Myrian Velasco
Marcia HiriartMarcia Hiriart
Marcia Hiriart
Nerve growth factor (NGF) was the first neurotrophin described. This neurotrophin contributes to organogenesis by promoting sensory innervation and angiogenesis in the endocrine and immune systems. Neuronal and non-neuronal cells produce and secrete NGF, and several cell types throughout the body express the high-affinity neurotrophin receptor TrkA and the low-affinity receptor p75NTR. NGF is essential for glucose-stimulated insulin secretion and the complete development of pancreatic islets. Plus, this factor is involved in regulating lipolysis and thermogenesis in adipose tissue. Immune cells produce and respond to NGF, modulating their inflammatory phenotype and the secretion of cytokines, contributing to insulin resistance and metabolic homeostasis. This neurotrophin regulates the synthesis of gonadal steroid hormones, which ultimately participate in the metabolic homeostasis of other tissues. Therefore, we propose that this neurotrophin’s imbalance in concentrations and signaling during metabolic syndrome contribute to its pathophysiology. In the present work, we describe the multiple roles of NGF in immunoendocrine organs that are important in metabolic homeostasis and related to the pathophysiology of metabolic syndrome.

24 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Rosa Isela Ortiz-HuidobroRosa Isela Ortiz-Huidobro
Rosa Isela Ortiz-Huidobro
PPPablo Pánico
Pablo Pánico
ASAna María Salazar
Ana María Salazar
Marcia HiriartMarcia Hiriart
Marcia Hiriart
POPatricia Ostrosky-Wegman
Patricia Ostrosky-Wegman
Type 2 Diabetes (T2D) is characterized by hyperglycemia due to pancreatic beta cell failure and the development of insulin resistance. Although high carbohydrate intake and arsenic exposure increase the risk of developing T2D, their interactions and mechanisms associated with changes in insulin signaling pathways that lead to beta-cell apoptosis remain unknown. We determined the effects of in vitro exposure for 48 and 72 h to arsenic (As, 2 µM), glucose (Gluc, 22 mM), and their interaction (As + Gluc) on the apoptosis in RINm5F insulinoma beta-cells and explored the possible mechanisms dependent on alterations in insulin signaling pathways. We found that arsenic induced early apoptosis, while glucose co-treatment reduced arsenic-induced apoptosis. Mechanistically, co-treatment with As + Gluc deregulates the PI3K/Akt pathway, increasing the activation of Akt and S6K1, whereas in the MAPK pathway decreases arsenic-induced ERK1/2 activation. Furthermore, in these cells we observed an increased calpain proteolytic activity and down-regulation of the pro-apoptotic Bax/Caspase-3 pathway, compared to the effects of arsenic alone. Overall, our results suggest that 48 and 72 h of glucose co-treatment mitigates the pro-apoptotic effect of arsenic in RINm5F cells. Notably, calpains appear to play a critical role in this response, whereas the Akt/S6K1 signaling axis shows significant changes compared to the control.

30 December 2025 in PLOS ONE
Verified
Journal Article
Open access
MVMyrian Velasco
Myrian Velasco
RORosa Isela Ortiz-Huidobro
Rosa Isela Ortiz-Huidobro
ASAna María Salazar
Ana María Salazar
Marcia HiriartMarcia Hiriart
Marcia Hiriart
POPatricia Ostrosky-Wegman
Patricia Ostrosky-Wegman
PPPablo Pánico
Pablo Pánico
Exposure to arsenic or sugary drinks can increase the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), although the mechanisms involved and its possible interactions remain unexplored. This work aimed to characterize the development of MASLD and their molecular mechanisms, induced in male Wistar rats consuming 20% sucrose (S), 50 ppm sodium arsenite (A), or both (A + S) through drinking water for 2 months. We found that rats consuming S developed liver steatosis and extensive fibrosis. Liver steatosis induced by S and A + S correlated with decreased calpain-1 protein abundance and calpain-dependent αII-spectrin proteolysis. We showed that calpain-1 inhibition in vitro induces lipid accumulation in hepatocytes probably by increasing PPARγ protein levels in the hepatic HepG2 cell line. Concordantly, PPARγ protein levels were increased in the livers of S-treated rats. A-treated rats did not develop steatosis, displayed decreased calpain-1 levels but its proteolytic activity remained intact. Treatment with A + S induced liver steatosis but displayed less fibrosis than S-treated rats. Although A + S reduced calpain-1 levels and activity, the levels of PPARγ were not induced in these rats. Our results suggest that liver steatosis induced by sucrose could be related with impaired calpain activity, which could promote PPARγ increase. However, some of these alterations induced by sucrose are attenuated by co-administering arsenic, suggesting that there are other calpain-dependent mechanisms involved in liver steatosis. The graphical abstract was generated using BioRender (License in S5 File).

10 November 2026 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
PPPablo Pánico
Pablo Pánico
MVMyrian Velasco
Myrian Velasco
Rosa Isela Ortiz-HuidobroRosa Isela Ortiz-Huidobro
Rosa Isela Ortiz-Huidobro
CLCarlos Larqué
Carlos Larqué
RERene Escalona
Rene Escalona
POPatricia Ostrosky‐Wegman
Patricia Ostrosky‐Wegman